KRON - Kronos Bio Inc Stock Price, Fair Value and News

$1.00-0.01 (-0.99%)

Delayed as of 06 Feb 2025, 01:06 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

KRON Price Action

Last 7 days

-1.0%

Last 30 days

4.1%

Last 90 days

12.2%

Trailing 12 Months

-7.3%

KRON RSI Chart

KRON Valuation

Market Cap

60.9M

Price/Earnings (Trailing)

-0.71

Price/Sales (Trailing)

4.79

Price/Free Cashflow

-0.78

KRON Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

KRON Fundamentals

KRON Revenue

Revenue (TTM)

12.7M

Rev. Growth (Yr)

158.45%

Rev. Growth (Qtr)

-11.83%

KRON Earnings

Earnings (TTM)

-85.6M

Earnings Growth (Yr)

55.03%

Earnings Growth (Qtr)

12.91%

KRON Profitability

Return on Equity

-77.02%

Return on Assets

-57.05%

Free Cashflow Yield

-127.42%

KRON Investor Care

Shares Dilution (1Y)

3.47%

Diluted EPS (TTM)

-1.43

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	10.5M	11.3M	12.7M	0
2023	5.0M	6.3M	5.9M	9.2M
2022	330.0K	871.0K	2.1M	3.9M
2021	635.0K	502.0K	372.0K	320.0K
2020	751.0K	800.0K	849.0K	898.0K
2019	0	0	0	702.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Kronos Bio Inc

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial; and Lanraplenib, a next-generation SYK inhibitor to treat the patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. The company was incorporated in 2017 and is headquartered in San Mateo, California.

CEO	Dr. Norbert W. Bischofberger Ph.D.
WEBSITE	https://kronosbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	104

Kronos Bio Inc Frequently Asked Questions

What is the ticker symbol for Kronos Bio Inc? What does KRON stand for in stocks?

KRON is the stock ticker symbol of Kronos Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kronos Bio Inc (KRON)?

As of Wed Feb 05 2025, market cap of Kronos Bio Inc is 60.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KRON stock?

You can check KRON's fair value in chart for subscribers.

Is Kronos Bio Inc a good stock to buy?

The fair value guage provides a quick view whether KRON is over valued or under valued. Whether Kronos Bio Inc is cheap or expensive depends on the assumptions which impact Kronos Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KRON.

What is Kronos Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Feb 05 2025, KRON's PE ratio (Price to Earnings) is -0.71 and Price to Sales (PS) ratio is 4.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KRON PE ratio will change depending on the future growth rate expectations of investors.